American Cyanamid Company

American Home Products Corporation

Eugene J Trybulski

Herbert J Brabander

Richard H Kramss

Amedeo A Failli

Thomas Joseph Caggiano

Jehan F Bagli

Jay Scott Shumsky

Mark A Ashwell

Albert J Molinari

Jing Zhang

Russell G Dushin

The present invention provides compounds of the general formula:

Tricyclic pyridine N-oxides vasopressin agonists

This invention concerns the use of a hydroxylic solvent in the preparation of enaminones from the corresponding amine N-oxides or propargylic amines via the general process outlined below: ##STR1##

Process for converting propargylic amine-N-oxides to enaminones

This invention relates to tricyclic non-peptide vasopressin antagonists which are useful in treating conditions where decreased vasopressin levels are desired, such as in congestive heart failure, in disease conditions with excess renal water reabsorption and in conditions with increased vascular resistance and coronary vasoconstriction, the compounds having the general structure: ##STR1##

3-Carboxamide derivatives of 5H-pyrrolo�2,1-c!�1,4!-benzodiazepines

This disclosure describes novel substituted oxotremorine derivatives of formula I having nitrogen, oxygen or sulfur groups and the prodrug forms of these derivatives. The compounds have cholinergic activity. Also disclosed are methods for treating diseases of the central nervous system in mammals employing the compounds, pharmaceutical preparations containing the compounds and the processes for the production of the compounds. ##STR1##

Substituted oxotremorine derivatives

Compounds of the Formulae I or II ##STR1## wherein Z and R.sub.1, are as described herein which compounds are muscarinic agonists useful in treating central cholinergic disfunction and pharmaceutical compositions containing the compounds.

(R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives

Substituted oxotremorine derivatives and pharmaceutical use thereof

Maleimide derivatives of oxotremorine and their alkylthiol addition products having the general formulae: ##STR1## wherein R.sub.1 and R.sub.2 are independently alkyl, hydroxyalkyl, acyloxy, trialkylsilyloxy or R.sub.1 and R.sub.2 taken together are substituted or unsubstituted pyrrolidine or piperidine, and pharmaceutical compositions for the treatment of central cholinergic disfunction.

Maleimide derivatives of oxotremorine

Compounds of the formula: ##STR1## wherein A is t-butoxy carbonyl, which compounds are useful as intermediates for preparing 1-Substituted-2-(3-amino-1-propynyl)pyrrolidine derivatives having cholinergic agonist activity.

Dibromovinyl and acetylene-1-pyrrolidinecarboxylic acid intermediates

This disclosure describes novel 3 or 4 substituted oxotremorine derivatives having polar substituted oxygen or sulfur groups. The compounds have cholinergic activity. Also disclosed are methods for treating diseases of the central nervous system in mammals employing the compounds, pharmaceutical preparations containing the compounds and processes for the production of the compounds.

3- or 4-substituted oxotremorine derivatives and a method of treating

Pharmaceutical compounds and compositions which may be represented by the following structural formula: ##STR1## wherein NR'' is selected from amino, (C.sub.1 -C.sub.6) alkylamino, dialkylamino or trialkylamino, pyrrolidino or piperidino. The compounds and compositions are useful in treating central cholinergic dysfunction in mammals.

(3-amino-1-propynyl)methylthiothiophene derivatives

Compounds of the formula: ##STR1## pharmaceutical compositions containing the compounds and methods of using the compounds in the treatment of central cholinergic disfunction in a mammal are disclosed.

1-substituted-2-(3-amino-1-propynyl)pyrrolidine derivatives

Pharmaceutical compounds and compositions which may be represented by the following structural formulae: ##STR1## where R is hydrogen or lower alkyl and NR'' is amino, (C.sub.1 -C.sub.6) alkylamino, dialkylamino, or trialkylamino, pyrrolidino or piperidino. The compounds are useful in treating central cholinergic disfunction in mammals.

Growing community of inventors

Park Ridge, NJ, United States of America

Eugene J Trybulski